Breaking News
December 10, 2018 - Some Brain Tumors May Respond to Immunotherapy, New Study Suggests
December 10, 2018 - Banning junk food ads to combat childhood obesity
December 10, 2018 - Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality
December 10, 2018 - Largest autism sequencing study to date yields 102 genes associated with ASD
December 10, 2018 - Statins associated with low risk of side effects
December 10, 2018 - Study explores how schools address adolescent self-harming practices
December 10, 2018 - Pregnancy in adolescence linked to increased risks of complications in young mothers
December 10, 2018 - Risk Analysis publishes special issue on communicating about Zika virus
December 10, 2018 - Botox May Help Prevent Post-Op A-Fib
December 10, 2018 - African-American mothers rate boys higher for ADHD
December 10, 2018 - Graphic warning labels cancel out cigarettes’ appeal to young people
December 10, 2018 - Australian researchers to study gas inhalational anaesthetic and likelihood of cancer return
December 10, 2018 - Individual neurons located within the brain have implications for psychiatric diseases
December 10, 2018 - Researchers improve bariatric surgery scoring system to extend prediction time for diabetic remission
December 10, 2018 - HPV type 16 or 18 associated with cervical cancer risk in young women
December 10, 2018 - Cervical cancer risk is higher in women with positive HPV, but no cellular abnormalities
December 10, 2018 - Combo therapy not needed if low RA disease activity achieved
December 10, 2018 - Novel therapeutic targets based on biology of aging show promise for Alzheimer’s disease
December 10, 2018 - UC San Diego professor receives NCI Outstanding Investigator Award for cancer research
December 10, 2018 - Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regeneration
December 10, 2018 - Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 10, 2018 - Study clarifies ApoE4’s role in dementia
December 10, 2018 - Eating disorders now a top priority with Australian Government
December 10, 2018 - Neuronal activity in the brain allows prediction of risky or safe decisions
December 10, 2018 - FDA Alerts Health Care Professionals and Patients Not to Use Drug Products Intended to be Sterile from Promise Pharmacy
December 10, 2018 - Improving dementia care and treatment saves thousands of pounds in care homes
December 10, 2018 - Heroin-assisted treatment can offer benefits, reduce harms
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
December 8, 2018 - Scientists overturn odds to make Parkinson’s discovery
December 8, 2018 - Health benefits of producing marula vinegar
December 8, 2018 - Failure of critical cellular energy sensor responsible for CKD progression, study finds
December 8, 2018 - Ethnicity can be reliable indicator of gut microbiota diversity
December 8, 2018 - Safe Sleep for Baby | NIH News in Health
Does a Financial Conflict of Interest Ever Expire?

Does a Financial Conflict of Interest Ever Expire?

image_pdfDownload PDFimage_print

Several weeks ago, I wrote about the silliness of the war between primary care societies and cardiology organizations about the new hypertension guideline.

Here’s the story thus far. Cardiology specialty organizations announced that the new cutoff for hypertension would now be a systolic blood pressure greater than 130 mm Hg. Primary care societies had announced earlier in the year that the appropriate cutoff was greater than 150 mm Hg in most patients.

The American Academy of Family Physicians and the American College of Physicians denounced the new cardiology-led guidelines. The American Heart Association and the American College of Cardiology countered with a publicity campaign to support their position.

I called it a “fake” war, because it made no scientific sense. Larry Husten, in his most recent CardioBrief post, corrected me, stating that the war was quite real.

On Feb. 5, 2018, the Baltimore Sun published an article by a family physician (Dr. Max Romano), who accused the cardiology guidelines committee for undisclosed financial conflicts of interest.

He wrote that certain members of the guideline committee had financial relationships dating back to 2013-2014, which had not been disclosed in the guidelines publication. He assumed that these 4-year-old relationships (regardless of the amounts or purposes) led the members of the guideline committee to dramatically widen the use of antihypertensive drugs, simply to promote the profits of the pharmaceutical companies that had previously funded them.

The attack by Dr. Romano may have been well-intentioned, but it was ill-informed for several reasons.

First, the Open Payments website contains only information about payments that are reported using specified definitions. The site reports the date when payments were made, which may not correspond to the dates that the relationship took place. (Payments may be delayed for months or years after a contract is completed.)

Second, nearly all antihypertensive drugs are now generic and very inexpensive. Hypertension is neither a source of revenue growth nor an area of innovation. The companies that will primarily profit from the change in the diagnostic criteria or treatment targets for hypertension are not those that were identified by Dr. Romano.

Third, the Open Payments system only reports recent financial relationships. It does not report relationships that occurred in 2009, 2004, 2001, 1998. If it did, Dr. Romano’s article would undoubtedly have been much longer.

Suppose that Dr. Romano could go back 5, 10 or 15 years. Are these older financial relationships relevant to his argument?

Some might say yes, that any payment of any type for any reason — even one that was 30 years old — creates a bias that should disqualify someone from serving on a guidelines committee.

Really?

Does any prior financial interaction, regardless of amount or purpose and regardless of the time period, disqualify someone?

All organizations that worry about conflicts of interests have a “sunset” provision. It is the identification of date before which the influence of a prior relationship is deemed to be irrelevant. You can argue about whether it should be 1, 3, 5 or 20 years. But at some point in time, the influence of that relationship becomes negligible.

I am sure that some will disagree. Some may propose that we should populate our guidelines committee only with people who have been placed in a hermetically sealed container since birth, which has shielded them from all microbes that could influence their cerebral development.

I guess we could do that, but how would these highly protected individuals ever know what the real world was like? How would they ever make informed judgments? Doesn’t one need to interact with the world to understand its limitations?

I certainly do not want to hear advice from people who don’t know what the world is really like. I certainly do not want to hear people analyze trials that have been supported by industry if they have never been involved in an industry-supported trial. How would they ever know what they are talking about?

Trust should be based on the integrity of individuals, not on their ability to pass some arbitrary test of “purity.”

Using a litmus test of “purity” means that you don’t need to do any work to figure out if someone is being intellectually honest. It is so much easier simply to create a stereotype. If you think about it, that process actually has a name — it is called “profiling,” and it is really bad news.

Interestingly, those who would routinely condemn “profiling” behavior in others have no qualms about doing it themselves. Welcome to today’s world.

Packer recently consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Novo Nordisk, Relypsa, Sanofi, Takeda, and ZS Pharma. He chairs the EMPEROR Executive Committee for trials of empagliflozin for the treatment of heart failure. He was previously the co-PI of the PARADIGM-HF trial and serves on the Steering Committee of the PARAGON-HF trial, but has no financial relationship with Novartis.

2018-02-14T10:30:00-0500

Tagged with:

About author

Related Articles